Russian scientists developed a new drug for cancer diagnostics and treatment

December 04, 2018

Russian researchers announced the development of a combined action drug based on ionizing radiation and bacterial toxin. Their total effect appeared to be 2,200 times stronger compared to that exerted by the radiation and toxin, separately. The drug affects tumor cells selectively providing better diagnostics and treatment of malignant tumors. These advances were reported in an article published in the Proceedings of the National Academy of Sciences.

Chemotherapy is widely used for treatment of cancerous diseases. However, it is associated with severe side effects (hair loss, nausea, loss of appetite, oedema, anemia, memory disorders, and so on) as the drugs affect the body in total and are accumulated throughout normal tissues. Moreover, the chemotherapy often requires repeated drug administration to overcome tumor propensity to relapse. A perfect anti-cancer drug should provide a powerful impact to all tumor cells at once to prevent their recovery.

The combined therapy proposed and realised by the Russian scientists appeared to be successful. "Just like modern armies deploy tanks, foot troops, and artillery, we also fight tumors using several mechanisms at once: ionising radiation and a strong toxin of bacterial origin," says Andrey Zvyagin, head of the Department of Biomedical Engineering at the Institute of Molecular Medicine, Sechenov University.

The drug developed by the scientists consists of a nanoparticles, as the core, with embedded radiopharmaceutical agent (a source of ionising beta-radiation), and a highly toxic toxin derived from bacterium Pseudomonas aeruginosa. The nanosized drug core is decorated with polymer to render the nanocomplex water miscible and biologically amiable and coupled with biological molecules, which represent the toxin fused with a targeting biomolecule by genetic engineering methods. The radiopharmaceutical agent is well secluded inside the nanoparticle and guarantees its side-effect-free targeted action to tumor cells. Blood vessels that feed the tumor have pores through which the drug enters the tumor from the blood flow. The targeting biomolecule binds itself with cancer cells causing them to accumulate in the primary and metastatic tumors. The radiopharmaceutical agent is able to affect the cells both in immediate proximity to the nanoparticles and up to 1 cm from them, providing for efficient therapy of considerable tumor masses. The toxin blocks the synthesis of proteins in the cells preventing them from restoration and dissemination.

The new drug was tested both on cells and laboratory animals: breast cancer (the most widely spread type of cancer in women) was grafted on a laboratory mouse, and after that the tested drug was administered to it. In experiments on cells, the effect of the combination was 2,200 times stronger than the effect from the separate use of its components. The efficiency of combined therapy was confirmed by experiments on laboratory mice. The drug not only treats, but also facilitates visualisation of the tumors, which makes it a diagnostical tool. The area of medicine that combines diagnostics and treatment is called theranostics.
-end-
The work was carried out together with scientists from N.I. Lobachevsky State University of Nizhny Novgorod, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, a company "Amplituda Science and Technology Center", and other research groups. The whole work, from the idea to the publishing of the article, was carried out in Russia.

Sechenov University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.